Top Markets
Coin of the day
Hubei Biocause Pharmaceutical Co., Ltd. Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

000627
Rangering i aksjer #9082
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a... Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
Aksjekurs
$0.2219522
Sist synkronisert: 2025-09-11
Markedsverdi
$1.10B
Endring (1 dag)
0.04%
Endring (1 år)
0.17%
Land
CN
Handel Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Inntekter for Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Inntekter i Sep 2024 TTM: $11.64B
Ifølge de nyeste økonomiske rapportene til Hubei Biocause Pharmaceutical Co., Ltd. er selskapets nåværende inntekter (TTM) $11.64B. I 2022 hadde selskapet inntekter på $7.19B en nedgang sammenlignet med inntektene i 2021, som var $7.80B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Hubei Biocause Pharmaceutical Co., Ltd. fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $11.64B 65.85%
2023 $7.02B -2.39%
2022 $7.19B -7.80%
2021 $7.80B 16.95%
2020 $6.67B -7.46%
2019 $7.21B 60.19%
2018 $4.50B -45.18%
2017 $8.21B 235.32%
2016 $2.45B 2,837.70%
2015 $83.33M -36.00%
2014 $130.20M -18.41%
2013 $159.58M 27.62%
2012 $125.04M -30.47%
2011 $179.84M -5.88%
2010 $191.07M 35.24%
2009 $141.29M 6.03%
2008 $133.26M 16.42%
2007 $114.46M 59.34%
2006 $71.83M 11.78%
2005 $64.26M 14.85%
2004 $55.95M 9.55%
2003 $51.07M 21.26%
2002 $42.12M -2.10%
2001 $43.02M 10.51%
2000 $38.93M 0.00%
Inntekter for lignende selskaper eller konkurrenter